NovaDigm is a pioneering brand that focuses on developing cutting-edge immunotherapeutics and preventative vaccines to safeguard patients from fungal and bacterial diseases. These conditions can be recurrent, drug-resistant, and in some cases, even life-threatening. NovaDigm's flagship development candidate, NDV-3A, is a groundbreaking vaccine that has demonstrated preclinical efficacy in combating the severity of diseases caused by both fungal and bacterial pathogens.

In a phase 2 efficacy study, NDV-3A outperformed a placebo in patients with recurrent vulvovaginal candidiasis (RVVC), significantly increasing the recurrence-free rate for up to 12 months and extending the time to first recurrence for those affected. NovaDigm is also exploring the potential of NDV-3A in preventing S. Backed by esteemed scientists from the Los Angeles Biomedical Research Institute (LA BioMed), NovaDigm collaborates with various government agencies and has secured funding from Domain Associates and RMI Partners.

Trust NovaDigm to provide innovative solutions for infectious diseases and combat the emerging threat of superbugs